VYNE Therapeutics (VYNE) Net Equity Issued and Repurchased (2017 - 2023)

VYNE Therapeutics' Net Equity Issued and Repurchased history runs 7 years deep, the most recent figure standing at $156000.0 for Q1 2023.

• Quarterly Net Equity Issued and Repurchased fell 89.98% year-over-year to $156000.0 in Q1 2023, while the trailing twelve-month figure through Dec 2023 was $156000.0 (down 26.07% YoY) and the FY2023 annual result came in at $156000.0, down 26.07% from the prior year.
• Net Equity Issued and Repurchased was $156000.0 for Q1 2023 at VYNE Therapeutics, up from -$1.3 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $73.1 million in Q1 2021 and bottomed at -$76.0 million in Q4 2021.
• A 5-year average of $6.3 million and a median of $2.1 million in 2019 frame the typical range for Net Equity Issued and Repurchased.
• Annual changes were most pronounced in 2019 — Net Equity Issued and Repurchased tumbled 7841.18% — and 2020, when it surged 2138.22%.
• VYNE Therapeutics' Net Equity Issued and Repurchased stood at $13.7 million in 2019, then plunged by 41.72% to $8.0 million in 2020, then plunged by 1050.96% to -$76.0 million in 2021, then jumped by 98.34% to -$1.3 million in 2022, then surged by 112.38% to $156000.0 in 2023.
• Business Quant data shows VYNE's Net Equity Issued and Repurchased at $156000.0 in Q1 2023, -$1.3 million in Q4 2022, and -$86000.0 in Q2 2022.